RxDoctor Payments DataLook up a doctor →

Abid Khan, MD

Psychiatry · Amityville, NYNPI 1932288735

Payments from drug & device makers

$625,922in general payments, 2019–2025

Across 630 payments — averaging $993.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$291K
  • E.r. Squibb & Sons, L.L.C.$151K
  • Otsuka America Pharmaceutical, Inc.$147K
  • Sunovion Pharmaceuticals Inc.$20K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$16K
  • Johnson & Johnson$531
  • plus $170 from 3 others

What the payments were for

  • Consulting fees$51,8258%
  • Speaking & faculty fees$495,09579%
  • Travel & lodging$60,15310%
  • Food & beverage$18,8493%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$625,922 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$255,642
Medicare patients
190
Services billed
2,941

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate19$51,329
Aripiprazole18$1,459
Divalproex Sodium50$1,354
Olanzapine34$535
Risperidone39$475
Haloperidol21$468
Quetiapine Fumarate28$432
Benztropine Mesylate40$353
Trazodone Hcl33$273
Ezetimibe12$235
Atorvastatin Calcium27$171
Gabapentin13$132
Levothyroxine Sodium21$108
Clonazepam18$103
Mirtazapine13$95

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$531$51,32919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Amityville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →